New [c,d]-Fused Purinediones: 2-Substituted 9-Methyl-4,5-dihydro-6H,8H-pyrimido-[1,2,3-cd]purine-8,10(9H)-diones

Ondrej Šimo, Alfonz Rybár,* Juraj Alföldi

Institute of Chemistry, Slovak Academy of Sciences, SK-84238 Bratislava, The Slovak Republic Fax + 42(7)373811; E-mail chembabo@savba.savba.sk

Received 20 January 1995


2-Alkyl- or 2-aryl-9-methyl-4,5-dihydro-6*H*,8*H*-pyrimido[1,2,3-cd]purine-8,10(9*H*)-diones **5** were obtained either by a four-step synthesis starting from 6-chloro-5-nitro-3-methylpyrimidine-2,4(1*H*,3*H*)-dione **(1)** via 9-amino-7-methyl-3,4-dihydro-2*H*-pyrimido[1,6-a]pyrimidine-6,8(1*H*,7*H*)-dione **(4)** and its reaction with the respective orthocarboxylates, or, alternatively, by a four-step process from 6-[(3-hydroxypropyl)amino]-3-methyl-5-nitrosopyrimidine-2,4(1*H*,3*H*)-dione via 8-alkyl- or 8-aryl-9-mesyloxypropyl-1-methyl-3,9-dihydro-1*H*-purine-2,6-diones **9** and their intramolecular alkylation in dimethylformamide (DMF) in the presence of potassium carbonate.

So far only two types of compounds with a pyrimido[1,2,3-cd]purine ring system have been reported, viz. 4,9-dimethyl-5,6-dihydropyrimidopurine¹ and the partly unsaturated 9-alkyl-4-substituted aryl derivatives;² the last-mentioned compounds revealed interesting anxiolytic and antihypertensive effects.

In extention of our studies on annulated purinediones, ³⁻⁶ we wish to present two new synthetic approaches to the pyrimido[1,2,3-cd]purine ring system. 2-Substituted 9-methyl-4,5-dihydro-6H,8H-pyrimido[1,2,3-cd]purine-8,10(9H)-diones 5 were obtained from 6-chloro-5-nitro-3-methylpyrimidine-2,4-(1H,3H)-dione⁷ (1), which was converted into the corresponding 6-[(3-hydroxypropyl)amino]-5-nitro derivative 2 by a nucleophilic replacement with 3-aminopropanol. Lengthy reflux of the latter

in DMF resulted in elimination of water originating from the side-chain hydroxy group in position 6 and the proton at N₁ of the pyrimidine derivative 2 and formation of 7-methyl-9-nitro-3,4-dihydro-2*H*-pyrimido[1,6-*a*]pyrimidine-6.8(1H.7H)-dione (3). The nitro group in position 5 of compounds 2 is prerequisite for closure of the second ring of pyrimidine, because it enhances acidity of the N₁ proton and thus stimulates the elimination of water. The analogous 6-(3-hydroxypropyl)amino derivative without the nitro group resisted condensation attempts, and even quadrupled reaction time (60 h) did not afford the required dehydration product. Nevertheless, cyclization of a derivative analogous to our intermediate 2, but without the methyl group in position 3 has already been reported;8 it was, however, necessary to extend the reaction time by three times (14 h). Hydrogenation of the nitro group of compound 3 yielded the bicyclic diamine 4, which is the precursor to formation of the third imidazole ring of the final products 5. The third ring was formed by reacting the intermediate 4 with orthocarboxylates in aprotic solvents under acid catalysis and elevated temperature.

The second method leading to products 5 is based upon closure of the third pyrimidine ring in the suitably 9-substituted purinedione precursor. The starting 9-(3-functionalized propyl) 8-substituted 1-methyl-3,9-dihyd-



838 Papers SYNTHESIS

ro-1*H*-purine-2,6-dione **9** was obtained from the known⁹ 6-[(3-hydroxypropyl)amino]-3-methyl-5-nitrosopyrimidine-2,4(1H,3H)-dione (6) by hydrogenation to the corresponding 5-amino derivative 7. Similarly to the first method, compound 7 was reacted with orthocarboxylates in an aprotic solvent and traces of acid at elevated temperature to yield 8-substituted 9-(3-hydroxypropyl)-1methyl-3,9-dihydro-1*H*-purine-2,6-diones **8**. Mesylation with mesyl chloride in the presence of an organic base afforded the corresponding 9-(3-mesyloxypropyl) derivatives 9, and subsequent intramolecular alkylation in the presence of alkali metal carbonate in an aprotic solvent at 110°C gave the final products 5. The cyclization of compounds 9 producing the pyrimidine ring proceeded smoothly and without formation of byproducts. On the other hand, attempts to convert 9-(3-hydroxypropyl) derivatives into the respective 9-(3-chloropropyl) analogues failed.

The bicyclic diamine 4 was also the starting material for the preparation of 9-methyl-4,5-dihydro-6*H*,8*H*-2-aza-pyrimido[1,2,3-cd]purine-8,10(9*H*)-dione (10) by nitrosation with nitrous acid in water. The structure of the new compounds was verified by elemental analysis, ¹H, ¹³C NMR and mass spectral data. Diamines 4 and 7 are air-oxygen sensitive. The aqueous and dimethyl sulfoxide solutions of 7 were so unstable that we were unable to measure its NMR spectra.

Scheme 3

Reagents were obtained from commercial suppliers and were used without further purification. Mps were determined with a hot stage microscope (Boetius) and are uncorrected. The ¹H (300 MHz) and ¹³C (75.45 MHz) NMR spectra were obtained on a Bruker AM-300 spectrometer. Chemical shifts were related to tetramethylsilane as an internal standard. Signals of compounds **5e**, **8e** and **9e** were assigned by means of 2D COSY experiments. Mass spectra were obtained on a Finnigan MAT SSQ 710 instrument using the electron impact ionization technique (100–210 °C, 70 eV). TLC was carried out on plates SILUFOL UV₂₅₄ (Kavalier, Votice, Czech Republic) in CHCl₃/MeOH (9:1).

Satisfactory elemental analyses were obtained for all new compounds: $C \pm 0.39$, $H \pm 0.30$, $N \pm 0.33$, $S \pm 0.37$ %.

6-[(3-Hydroxypropyl)amino]-3-methyl-5-nitropyrimidine-2,4(1*H*,3*H*)-dione (2):

3-Aminopropanol (30.0 g, 0.40 mol) was added to a stirred suspension of 6-chloro-3-methyl-5-nitropyrimidine-2,4(1H,3H)-dione (1; 20.5 g, 0.10 mol) in H₂O (165 mL). Dissolution of compound 1 was slightly exothermic. The mixture was refluxed for 10 min, cooled to 40 °C, and acidified with 5 M aq HCl to pH 1. The separated crystals were filtered off and crystallized from H₂O (330 mL). Yield: 5.9 g (79 %), mp 189–191 °C (H₂O/EtOH).

 $^1{\rm H}$ NMR (DMSO- d_6): $\delta=1.83$ (quin, 2 H, NCH $_2{\rm CH_2}$), 3.18 (s, 3 H, N – CH $_3$), 3.59 (t, 2 H, NCH $_2$), 3.66 (br t, 2 H, CH $_2{\rm OH}$), 10.2 (br s, 1 H, 6-NH).

¹³C NMR (DMSO- d_6): δ = 27.0 (N – CH₃), 30.9 (NCH₂CH₂), 40.0 (NCH₂), 58.3 (CH₂OH), 109.3 (C-5), 148.4 (C-6), 151.8 (C-2), 155.9 (C-4).

MS: m/z (%) = 244 (M⁺, 67), 226 (100), 208 (57), 198 (25), 196 (26), 180 (64), 167 (17), 136 (19), 123 (27), 111 (30), 96 (25), 83 (75).

7-Methyl-9-nitro-3,4-dihydro-2*H*-pyrimido[1,6-*a*]pyrimidine-6,8(1*H*,7*H*)-dione (3):

Compound 2 (8.3 g, 34 mmol) in DMF (85 mL) was refluxed for 14 h, the solvent was removed under diminished pressure and the dry residue was crystallized from H_2O (150 mL, charcoal). Yield: 5.9 g (79%), mp 239–241 °C ($H_2O/EtOH$).

¹H NMR (DMSO- d_6): δ = 2.07 (m, 2H, H-3), 3.22 (s, 3H, N7-CH₃), 3.58 (m, 2H, H-2), 3.96 (m, 2H, H-4), 10.5 (br s, 1H, N1-H). ¹³C NMR (DMSO- d_6): δ = 18.2 (C-3), 27.7 (N7-CH₃), 39.8 (C-2), 41.6 (C-4), 109.3 (C-9), 148.4 (C-9a), 151.2 (C-6), 155.0 (C-8). MS: m/z (%) = 226 (M⁺, 45), 208 (85), 196 (20), 180 (11), 165 (9), 151 (7), 124 (17), 122 (16), 95 (18), 85 (39), 83 (100).

9-Amino-7-methyl-3,4-dihydro-2H-pyrimido[1,6-a]pyrimidine-6,8(1H,7H)-dione (4):

A suspension of compound 3 (6.1 g, 27 mmol) in $\rm H_2O$ (320 mL) was hydrogenated over Pt/C (410 mg, 10%) at 1 bar and r.t. for ca. 10 h; the originating amine dissolved in the medium. The catalyst was then filtered off and the aqueous solution, concentrated to 15 mL, was stored in a refrigerator overnight and the separated crystals were filtered off. Yield: 4.7 g (88%), mp 170–172°C (EtOH).

¹H NMR (DMSO- d_6): δ = 1.99 (m, 2H, H-3), 3.21 (s, 3H, N7-CH₃), 3.35 (m, 2H, H-2), 3.83 (m, 2H, H-4), 6.7 (br s, 1H, N1-H). ¹³C NMR (DMSO- d_6): δ = 20.5 (C-3), 27.3 (N7-CH₃), 38.4 (C-2), 40.6 (C-4), 93.4 (C-9), 144.2 (C-9a), 149.5 (C-6), 158.8 (C-8). MS: m/z (%) = 196 (M⁺, 100), 181 (4), 167 (7), 137 (6), 123 (5),

MS: m/z (%) = 196 (M⁺, 100), 181 (4), 167 (7), 137 (6), 123 (5) 111 (14), 96 (9), 84 (40), 85 (38).

5-Amino-6-[(3-hydroxypropyl)amino]-3-methylpyrimidine-2,4(1*H*,3*H*)-dione (7):

A suspension of 6-[(3-hydroxypropyl)amino]-3-methyl-5-nitrosopyrimidine-2,4(1H,3H)-dione (6; 10.5 g, 46 mmol) in EtOH (210 mL) was hydrogenated over Pt/C (730 mg, 10 %) at 1 bar and r.t. for ca. 3 h, during which the purple-red suspension turned light brown. The mixture was evaporated to dryness under reduced pressure and the product was crystallized from H_2O (180 mL), after removal of the catalyst. Yield: 5.9 g (60 %), mp 197–199 °C (H_2O / EtOH).

MS: m/z (%) = 214 (M⁺, 100), 196 (64), 183 (39), 169 (64), 155 (73), 128 (9), 110 (11), 98 (23), 84 (27).

8-Alkyl- or 8-Aryl-9-(3-hydroxypropyl)-1-methyl-3,9-dihydro-1*H*-purine-2,6-diones 8; General Procedure:

A mixture containing compound 7 (2.15 g, 10 mmol), DMF (25 mL), trimethyl or triethyl orthoalkanoate or orthobenzoate (15 mmol) and p-toluenesulfonic acid (8-12 mg) was heated with stirring at 90°C (3 h for 8e, f; 4 h for 8a, c, d; 7 h for 8b). The volatile components were distilled off under reduced pressure after the catalytical amount of p-toluenesulfonic acid was neutralized with ethanolic ammonia. The dry residue was crystallized from a suitable solvent in the presence of charcoal.

8-Unsubstituted Derivative (8a):

Yield: 76%; mp 248-250°C (EtOH).

¹H NMR (DMSO- d_6): δ = 1.91 (quin, 2 H, NCH₂CH₂), 3.26 (s, 3 H, N1-CH₃), 3.48 (t, 2 H, N9-CH₂), 4.18 (t, 2 H, CH₂OH), 7.76 (s, 1 H, H-8).

 $^{13}\mathrm{C}$ NMR (DMSO- d_6): $\delta=27.0$ (N1-CH $_3$), 32.4 (NCH $_2$ CH $_2$), 41.1 (N9-CH $_2$), 57.3 (CH $_2$ OH), 114.9 (C-5), 137.0 (C-8), 138.6 (C-4), 150.8 (C-2), 157.5 (C-6).

MS: m/z (%) = 224 (M⁺, 84), 206 (29), 194 (7), 179 (25), 166 (7), 149 (50), 139 (35), 122 (100), 109 (35), 95 (10).

8-Methyl Derivative (8b):

Yield: 61%; mp 195-197°C (EtOH).

¹H NMR (DMSO- d_6): δ = 1.85 (quin, 2 H, NCH₂CH₂), 2.42 (s, 3 H, C8-CH₃), 3.23 (s, 3 H, N1-CH₃), 3.49 (t, 2 H, N9-CH₂), 4.11 (t, 2 H, CH₂OH).

¹³C NMR (DMSO- d_6): δ = 12.9 (C8-CH₃), 27.0 (N1-CH₃), 32.0 (NCH₂CH₂), 40.3 (N9-CH₂), 57.4 (CH₂OH), 113.0 (C-5), 139.2 (C-4), 144.2 (C-8), 150.8 (C-2), 157.2 (C-6).

MS: m/z (%) = 238 (M⁺, 77), 207 (7), 193 (13), 179 (9), 164 (10), 153 (35), 137 (100), 122 (20), 109 (24), 96 (8).

8-Ethyl Derivative (8c):

Yield: 41 %; mp 218-219°C (EtOH).

¹H NMR (DMSO- d_6): $\delta = 1.43$ (t, 3 H, CH₂CH₃), 1.85 (quin, 2 H, NCH₂CH₂), 2.79 (q, 2 H, C8-CH₂), 3.28 (s, 3 H, N1-CH₃), 3.50 (t, 2 H, N9-CH₂), 4.12 (t, 2 H, CH₂OH).

¹³C NMR (DMSO- d_6): δ = 11.1 (CH₂CH₃), 19.3 (C8-CH₂), 27.0 N1-CH₃), 32.2 (NCH₂CH₂), 40.0 (N9-CH₂), 57.4 (CH₂OH), 113.1 (C-5), 139.2 (C-4), 148.2 (C-8), 150.8 (C-2), 157.3 (C-6).

MS: m/z (%) = 252 (M⁺, 100), 234 (4), 221 (13), 207 (21), 193 (8), 179 (21), 167 (42), 150 (20), 136 (17), 123 (68), 109 (7).

8-Propyl Derivative (8d):

Yield: 48%; mp 211-213°C (dioxane/EtOH).

¹H NMR (DMSO- d_6): δ = 1.06 (t, 3 H, CH₂CH₂CH₃), 1.81 (sext, 2 H, C8-CH₂CH₂), 1.84 (quin, 2 H, N9-CH₂CH₂), 2.73 (C8-CH₂), 3.27 (t, 2 H, N1-CH₃), 3.50 (t, 2 H, N9-CH₂), 4.12 (t, 2 H, CH₂OH).
¹³C NMR (DMSO- d_6): δ = 13.7 (CH₂CH₂CH₃), 19.9 (C8-CH₂CH₂), 26.9 (C8-CH₂), 27.7 (N1-CH₃), 32.3 (N9-CH₂CH₂), 40.0 (N9-CH₂), 113.2 (C-5), 139.1 (C-4), 147.2 (C-8), 150.7 (C-2), 157.2 (C-6).

MS: m/z (%) = 266 (M⁺, 30), 238 (10), 235 (17), 221 (10), 194 (100), 180 (32), 162 (17), 150 (5), 137 (24), 122 (8), 109 (4).

8-Butyl Derivative (8e):

Yield: 45%; mp 190–192°C (THF/methyl tert-butyl ether).

¹H NMR (DMSO- d_6): δ = 1.02 (t, 3 H, CH₂CH₂CH₃), 1.48 (sext, 2 H, C8-CH₂CH₂CH₂), 1.78 (quin, 2 H, C8-CH₂CH₂), 1.83 (quin, 2 H, N9-CH₂CH₂), 2.76 (t, 2 H, C8-CH₂), 3.28 (s, 3 H, N1-CH₃), 3.51 (t, 2 H, N9-CH₂), 4.12 (t, 2 H, CH₂OH).

 $^{13}\text{C NMR}$ (DMSO- d_6): $\delta = 13.7$ (CH₂CH₂CH₃), 21.7 (C8-CH₂CH₂CH₂), 25.5 (C8-CH₂CH₂), 26.9 (C8-CH₂), 27.0 (N1-CH₃), 32.3 (N9-CH₂CH₂), 40.0 (N9-CH₂), 57.4 (CH₂OH), 113.2 (C-5), 139.1 (C-4), 147.3 (C-8), 150.7 (C-2), 157.2 (C-6).

MS: m/z (%) = 280 (M⁺, 13), 265 (2), 251 (13), 238 (29), 221 (12), 207 (6), 194 (100), 180 (35), 162 (9), 150 (4), 122 (4), 109 (3).

8-Phenyl Derivative (8f):

Yield: 34%; mp 298-301°C (H₂O/EtOH).

¹H NMR (DMSO- d_6): δ = 1.80 (quin, 2 H, N9-CH₂CH₂), 3.32 (s, 3 H, N1-CH₃), 3.41 (t, 2 H, N9-CH₂), 4.28 (t, 2 H, CH₂OH), 7.6–7.8 (m, 5 H, H_{arom}).

 13 C NMR (DMSO- d_6): = 27.1 (N1-CH₃), 32.2 (N9-CH₂CH₂), 41.7 (N9-CH₂), 57.5 (CH₂OH), 114.4 (C-5), 128.5, 128.7, 129.4, 129.5, (C₆H₅), 140.2 (C-4), 145.8 (C-8), 150.8 (C-2), 157.5 (C-6).

MS: m/z (%) = 300 (M⁺, 100), 282 (58), 255 (24), 242 (14), 225 (39), 215 (12), 198 (47), 194 (26), 185 (11), 162 (18), 144 (31), 129 (16), 117 (43), 104 (87).

8-Alkyl- or 8-Aryl-9-(3-mesyloxypropyl)-1-methyl-3,9-dihydro-1*H*-purine-2,6-diones 9; General Procedure:

Et₃N (0.30 g, 0.42 mL, 3 mmol) added to a stirred and cooled (0-5°C) suspension of compound **8** (2 mmol) in CH₂Cl₂ (15 mL for **8c-e**, 20 mL for **8a, b, f**) afforded a solution into which mesyl chloride (0.25 g, 0.17 mL, 2.2 mmol) in CH₂Cl₂ (7 mL) was dripped at the same temperature over 15 min. The mixture was stirred without cooling (5°C \rightarrow r.t.) for 1 h and the solvent was removed under diminished pressure. Water (3 mL) was added to the dry residue, the crystalline product (9a, b, f) was filtered off, or the solution was stored in a refrigerator overnight and the crystals formed were filtered off (9c, d), or the product was taken from the solution with CH₂Cl₂ (2 × 15 mL), the solvent was concentrated to about 4 mL under reduced pressure and the crystals formed after addition of methyl *tert*-butyl ether (20 mL) were filtered off (9e).

8-Unsubstituted Derivative (9a):

Yield: 58%; mp 163-165°C (MeOH/EtOH).

¹H NMR (CDCl₃): δ = 2.20 (quin, 2 H, N9-CH₂CH₂), 3.30 (s, 3 H, N1-CH₃), 3.32 (s, 3 H, SO₂CH₃), 4.25 (t, 2 H, N9-CH₂), 4.31 (t, 2 H, OCH₂), 7.81 (s, 1 H, H-8).

 $^{13}\text{C NMR (CDCl}_3): \delta = 27.1 \text{ (N1-CH}_3), 29.0 \text{ (SO}_2\text{CH}_3), 36.7 \text{ (N9-CH}_2\text{CH}_2), 47.6 \text{ (N9-CH}_2), 67.3 \text{ (OCH}_2), 115.1 \text{ (C-5), 136.9 (C-8), 138.6 (C-4), 150.8 (C-2), 157.6 (C-6).}$

MS: m/z (%) = 206 (M – CH₃SO₃H, 76), 177 (3), 149 (100), 121 (61), 93 (9).

8-Methyl Derivative (9b):

Yield: 72%; mp 165–167°C (MeOH).

¹H NMR (CDCl₃): δ = 2.14 (quin, 2 H, N9-CH₂CH₂), 2.45 (s, 3 H, C8-CH₃), 3.26 (s, 3 H, N1-CH₃), 3.27 (s, 3 H, SO₂CH₃), 4.18 (t, 2 H, N9-CH₂), 4.38 (t, 2 H, OCH₂).

¹³C NMR (CDCl₃): δ = 12.9 (C8-CH₃), 27.0 (N1-CH₃), 28.6 (SO₂CH₃), 36.6 (N9-CH₂CH₂), 45.7 (N9-CH₂), 67.4 (OCH₂), 113.0 (C-5), 139.2 (C-4), 143.9 (C-8), 150.8 (C-2), 157.1 (C-6).

MS: m/z (%) = 220 (M – CH₃SO₃H, 100), 163 (99), 135 (50), 107 (5), 83 (65).

8-Ethyl Derivative (9c):

Yield: 62%; mp 142-144°C (acetone).

¹H NMR (CDCl₃): δ = 1.34 (t, 3 H, C8-CH₂CH₃), 2.13 (quin, 2 H, N9-(CH₂CH₂), 2.79 (q, 2 H, C8-CH₂), 3.27 (s, 3 H, N1-CH₃), 3.28 (s, 3 H, SO₂CH₃), 4.17 (t, 2 H, N9-CH₂), 4.35 (t, 2 H, OCH₂).

 $^{13}\text{C NMR (CDCl}_3): \delta = 11.0 \text{ (C8-CH}_2\text{CH}_3), 19.3 \text{ (C8-CH}_2), 27.0 \text{ (N1-CH}_3), 28.7 \text{ (SO}_2\text{CH}_3), 36.6 \text{ (N9-CH}_2\text{CH}_2), 45.8 \text{ (N9-CH}_2), 67.4 \text{ (OCH}_2), 113.0 \text{ (C-5), 139.2 (C-4), 148.2 (C-8), 150.8 (C-2), 157.2 (C-6).}$

MS: m/z (%) = 234 (M – CH₃SO₃H, 100), 177 (95), 149 (30), 121 (3), 98 (38), 96 (77).

8-Propyl Derivative (9d):

Yield: 52%; mp 141-143°C (acetone).

¹H NMR (CDCl₃): δ = 1.05 (t, 3 H, C8-CH₂CH₂CH₃), 1.82 (sext, 2 H, C8-CH₂CH₂), 2.13 (quin, 2 H, N9-CH₂CH₂), 2.73 (t, 2 H, C8-CH₂), 3.27 (s, 3 H, N1-CH₃), 3.28 (s, 3 H, SO₂CH₃), 4.18 (t, 2 H, N9-CH₂), 4.34 (t, 2 H, OCH₂).

 $^{13}\text{C NMR}$ (CDCl₃): $\delta = 13.7$ (C8-CH₂CH₂CH₃), 19.9 (C8-CH₂CH₂), 27.0 (N1-CH₃), 27.7 (C8-CH₂), 28.9 (SO₂CH₃), 36.6 (N9-CH₂CH₂), 45.7 (N9-CH₂), 67.4 (OCH₂), 113.1 (C-5), 139.1 (C-4), 147.1 (C-8), 150.8 (C-2), 157.2 (C-6).

MS: m/z = 248 (M - CH₃SO₃H, 45), 220 (100), 191 (45), 162 (14), 135 (12), 107 (7), 96 (20).

8-Butyl Derivative (9e):

Yield: 55%; mp 131-133°C (acetone/MeOH).

¹H NMR (CDCl₃): δ = 1.01 (t, 3 H, CH₂CH₂CH₃), 1.48 (sext, 2 H, C8-CH₂CH₂CH₂), 1.78 (quin, 2 H, C8-CH₂CH₂), 2.15 (quin, 2 H, N9-CH₂CH₂), 2.80 (t, 2 H, C8-CH₂), 3.28 (2 s, 6 H, N1-CH₃, SO₂CH₃), 4.19 (t, 2 H, N9-CH₁), 4.36 (t, 2 H, OCH₂).

 $^{13}\text{C NMR}$ (CDCl₃): $\delta = 13.7$ (CH₂CH₂CH₃), 21.7 (C8-CH₂CH₂CH₂), 25.3 (C8-CH₂CH₂), 27.0 (N1-CH₃), 28.6 (C8-CH₂), 28.8 (SO₂CH₃), 36.6 (N9-CH₂CH₂), 45.8 (N9-CH₂), 67.4 (OCH₂), 112.1 (C-5), 139.0 (C-4), 147.5 (C-8), 150.7 (C-2), 156.7 (C-6).

MS: m/z (%) = 262 (M – CH₃SO₃H, 17), 233 (16), 220 (100), 162 (17), 135 (17), 107 (5), 96 (17).

8-Phenyl Derivative (9f):

Yield: 85%; mp 179–180°C (MeOH).

¹H NMR (CDCl₃): δ = 2.10 (quin, 2 H, N9-CH₂CH₂), 3.17 (s, 3 H, N1-CH₃), 3.32 (s, 3 H, SO₂CH₃), 4.00 (t, 2 H, N9-CH₂), 4.22 (t, 2 H, OCH₂), 7.60–7.95 (m, 5 H, H_{arom}).

 $^{13}\mathrm{C\ NMR\ (CDCl_3)}$: $\delta=27.1\ (N1\text{-}CH_3),\,28.7\ (SO_2\mathrm{CH_3}),\,36.5\ (N9\text{-}CH_2\mathrm{CH_2}),\,45.6\ (N9\text{-}CH_2),\,67.1\ (OCH_2),\,114.4\ (C\text{-}5),\,128.6,\,128.8,\,129.2,\,129.8\ (C_6\mathrm{H_5}),\,140.1\ (C\text{-}4),\,145.6\ (C\text{-}8),\,150.8\ (C\text{-}2),\,157.4\ (C\text{-}6).$

840 Papers SYNTHESIS

MS: m/z (%) = 282 (M – CH₃SO₃H, 100), 225 (69), 197 (30), 144 (51), 117 (77), 113 (17).

2-Alkyl- or 2-Aryl-9-methyl-4,5-dihydro-6*H*,8*H*-pyrimido[1,2,3-*cd*] purine-8,10(9*H*)-diones 5; General Procedures:

Method A:

A mixture of compound 4 (1.96 g, 10 mmol), DMF (15 mL), trimethyl or triethyl orthoalkanoate or orthobenzoate (15 mmol) and p-toluenesulfonic acid (10-15 mg) was heated with stirring (1.5 h for 5d; 2.5 h for 5a, e; 3 h for 5b; 3.5 h for 5c; 4 h for 5f). The cooled mixture was neutralized with ethanolic ammonia and the volatile components were distilled off under diminished pressure. The dry distillation residue was crystallized from a suitable solvent.

Method B:

Compound 9 (2.0 mmol) in DMF (16 mL) was stirred with K_2CO_3 (0.33 g, 2.4 mmol) and heated to 110 °C (10 min for $\bf 5f$; 20 min for $\bf 5d$; 30 min for $\bf 5b$; 60 min for $\bf 5c$; 90 min for $\bf 5a$). DMF was distilled off in vacuo, the residue was extracted with CHCl₃ (3 × 100 mL), the solvent was removed under reduced pressure and the dry residue was crystallized from a suitable solvent (charcoal) ($\bf 5a-c$, $\bf f$), or the chloroformic solution was concentrated to a minimal volume to which methyl *tert*-butyl ether was added. The solution was stored overnight and the separated crystals were filtered off ($\bf 5d$).

2-Unsubstituted Derivative (5a):

Yield: 57% (Method A); 52% (B); mp 321–322°C (EtOH). ¹H NMR (CDCl₃): δ = 2.29 (quin, 2 H, H-5), 3.30 (s, 3 H, N9-CH₃), 3.92 (t, 2 H, H-4), 4.20 (t, 2 H, H-6), 7.85 (s, 1 H, H-2).

 $^{13}\mathrm{C}$ NMR (CDCl₃): $\delta = 20.5$ (C-5), 27.5 (N9-CH₃), 38.6 (C-4), 39.7 (C-6), 113.1 (C-10a), 135.6 (C-2), 138.0 (C-10b), 149.8 (C-8), 156.8 (C-10).

MS: $m/z = 206 \text{ (M}^+, 73), 149 (100), 121 (71), 93 (10).$

2-Methyl Derivative (5b):

Yield: 67% (A); 59% (B); mp 337-339°C (EtOH).

¹H NMR (CDCl₃): δ = 2.28 (quin, 2 H, H-5), 2.43 (s, 3 H, C2-CH₃), 3.28 (s, 3 H, N9-CH₃), 3.92 (t, 2 H, H-4), 4.08 (t, 2 H, H-6).

 13 C NMR (CDCl₃): δ = 12.4 (C2- $^{\circ}$ CH₃), 20.6 (C-5), 27.5 (N9- $^{\circ}$ CH₃), 38.6 (C-4), 39.7 (C-6), 114.0 (C-10a), 138.4 (C-10b), 148.0 (C-2), 149.7 (C-8), 156.5 (C-10).

MS: m/z (%) = 220 (M⁺, 100), 163 (99), 135 (53), 83 (70).

2-Ethyl Derivative (5c):

Yield: 51 % (A); 39 % (B); mp 199-200°C (EtOH).

¹H NMR (CDCl₃): δ = 1.33 (t, 3 H, C2-CH₂CH₃), 2.29 (quin, 2 H, H-5), 2.78 (q, 2 H, C2-CH₂), 3.30 (s, 3 H, N9-CH₃), 3.90 (t, 2 H, H-4), 4.10 (t, 2 H, H-6).

¹³C NMR (CDCl₃): δ = 10.9 (C2-CH₂CH₃), 19.4 (C2-CH₂CH₃), 20.6 (C-5), 27.4 (N9-CH₃), 38.6 (C-4), 39.7 (C-6), 111.7 (C-10a), 138.4 (C-10b), 147.8 (C-2), 149.7 (C-8), 156.6 (C-10).

MS: m/z = 234 (M⁺, 93), 177 (100), 149 (47), 97 (70), 96 (65).

2-Propyl Derivative (5d):

Yield: 63 % (A); 58 % (B); mp 159-162°C (dioxane)

¹H NMR (CDCl₃): δ = 1.14 (t, 3 H, CH₂CH₂CH₃), 1.78 (sext, 2 H, C2-CH₂CH₂), 2.29 (quin, 2 H, H-5), 2.73 (t, 2 H, C2-CH₂), 3.28 (s, 3 H, N9-CH₃), 3.90 (t, 2 H, H-4), 4.10 (t, 2 H, H-6).

3 H, N9-CH₃), 3.90 (t, 2 H, H-4), 4.10 (t, 2 H, H-6). ¹³C NMR (CDCl₃): δ = 13.6 (CH₂CH₂CH₃), 19.9 (C2-CH₂CH₂), 20.5 (C-5), 27.4 (N9-CH₃), 27.8 (C2-CH₂), 38.6 (C-4), 39.7 (C-6), 111.8 (C-10a), 138.3 (C-10b), 146.7 (C-2), 149.7 (C-8), 156.6 (C-10). MS: m/z = 248 (M⁺, 52), 220 (82), 219 (49), 191 (72), 162 (42), 135 (20), 107 (9), 96 (11). 2-Butyl Derivative (5e):

Yield: 56% (A); mp 150-151°C (EtOH).

¹H NMR (CDCl₃): δ = 1.02 (t, 3 H, CH₂CH₂CH₃), 1.48 (sext, 2 H, CH₂CH₂CH₃), 1.75 (quin, 2 H, C-2-CH₂CH₂), 2.29 (quin, 2 H, H-5), 2.76 (t, 2 H, C2-CH₂), 3.29 (s, 3 H, N9-CH₃), 3.92 (t, 2 H, H-4), 4.11 (t, 2 H, H-6).

¹³C NMR (CDCl₃): δ = 13.6 (CH₂CH₂CH₃), 20.6 (C-5), 21.6 (CH₂CH₂CH₃), 25.5 (C2-CH₂CH₂), 27.4 (N9-CH₃), 28.5 (C2-CH₂), 38.6 (C-4), 39.7 (C-6), 118.8 (C-10 a), 138.3 (C-10 b), 146.8 (C-2), 149.7 (C-8), 156.6 (C-10).

MS: m/z = 262 (M⁺, 29), 233 (27), 220 (100), 162 (34), 135 (38), 83 (45).

2-Phenyl Derivative (5f):

Yield: 81 % (A); 85 % (B); mp 276-280 °C (EtOH/H₂O).

¹H NMR (CDCl₃): δ = 2.30 (quin, 2 H, H-5), 3.33 (s, 3 H, N9-CH₃), 4.00 (t, 2 H, H-4), 4.40 (t, 2 H, H-6), 7.40–7.95 (m, 5 H, C2-Ph). ¹³C NMR (CDCl₃): δ = 20.9 (C-5), 27.6 (N9-CH₃), 39.7 (C-4), 42.8 (C-6), 113.3 (C-10a), 128.8, 128.9, 129.3, 129.5 (C₆H₅), 134.3 (C-8), 139.5 (C-10b), 149.7 (C-8), 158.8 (C-10).

MS: m/z = 282 (M⁺, 89), 225 (67), 197 (20), 145 (64), 144 (64), 117 (100), 113 (24), 103 (20), 89 (14), 77 (18).

9-Methyl-4,5-dihydro-6*H*,8*H*-2-azapyrimido[1,2,3-*cd*]purine-8,10(9*H*)-dione (10):

Conc. HCl (0.9 mL, 10 mmol) was dripped into a suspension of compound 4 (1.96 g, 10 mmol) in $\rm H_2O$ (30 mL). A solution of NaNO₂ (0.76 g, 11 mmol) in $\rm H_2O$ (2 mL) was added to the violet solution of 4 · HCl with stirring at 10 °C over 5 min. The violet colour of the solution disappeared and a colourless fine-crystalline product separated. Stirring was continued at 10 °C for 1 h until the reaction was complete and the filtered product was crystallized from $\rm H_2O$. Yield: 1.01 g (49 %), mp 268–269 °C ($\rm H_2O$).

¹H NMR (CDCl₃): δ = 2.38 (quin, 2 H, H-5), 3.32 (s, 3 H, N9-CH₃), 3.96 (t, 2 H, H-4), 4.55 (t, 2 H, H-6).

¹³C NMR (CDCl₃): δ = 20.4 (C-5), 27.9 (N9-CH₃), 39.2 (C-4), 43.1 (C-6), 122.4 (C-10a), 139.8 (C-10b), 149.6 (C-8), 155.4 (C-10). MS: m/z = 207 (M⁺, 100), 179 (23), 151 (24), 123 (43), 108 (34), 94 (23).

Financial support from the Slovak Grant Agency (project 2/568/93) is gratefully acknowledged.

- (1) Yakont, S. M. A.; Pederson, E. B. Chem. Scr. 1989, 29, 185.
- (2) Tseng, Sh. S.; Epstein, J. W.; Lewin, J. I. U.S. Patent 4904658, 1990; Chem. Abstr. 1990, 113, 115336.
- (3) Hesek, D.; Rybár, A.; Považanec, F.; Martvoň, A.; Kováč, J. Collect. Czech. Chem. Commun. 1988, 53, 319.
- (4) Hesek, D.; Tegza, M.; Rybár, A.; Považanec, F. Synthesis 1989,
- (5) Hesek, D.; Rybár, A.; Bella, J. Synthesis 1991, 625.
- (6) Hesek, D.; Rybár, A. Monatsh. Chem. 1993, 124, 1143.
- (7) Daves, Jr., G.D.; Robins, R.K.; Cheng, C.C. J. Am. Chem. Soc. 1962, 84, 1724.
- (8) Uhlmann, E.; Pfleiderer, W. Heterocycles 1981, 15, 437.
- (9) Pfleiderer, W.; Bunting, J. W.; Perrin, D. P.; Nübel, G. Chem. Ber. 1966, 99, 3503.